Robert Belshe

Summary

Affiliation: Saint Louis University
Country: USA

Publications

  1. ncbi request reprint A century of influenza prevention in St. Louis
    Robert B Belshe
    Division of Infectious Diseases, Allergy and Immunology Department of Internal Medicine at Saint Louis University School of Medicine, USA
    Mo Med 109:119-23. 2012
  2. pmc Efficacy results of a trial of a herpes simplex vaccine
    Robert B Belshe
    Division of Infectious Diseases, Allergy, and Immunology, Saint Louis University, St Louis, MO 63104, USA
    N Engl J Med 366:34-43. 2012
  3. ncbi request reprint Current status of live attenuated influenza virus vaccine in the US
    Robert B Belshe
    Health Science Center, Division of Infectious Diseases, Saint Louis University, 3035 Vista at Grand Blvd, St Louis, MO 63110, USA
    Virus Res 103:177-85. 2004
  4. ncbi request reprint Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years
    Robert B Belshe
    Center for Vaccine Development, Saint Louis University School of Medicine, St Louis, MO 63110, USA
    Clin Infect Dis 39:920-7. 2004
  5. ncbi request reprint Serum antibody responses after intradermal vaccination against influenza
    Robert B Belshe
    Department of Internal Medicine, Division of Infectious Diseases and Immunology, Saint Louis University, St Louis, MO 63110, USA
    N Engl J Med 351:2286-94. 2004
  6. ncbi request reprint Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children
    Robert B Belshe
    Saint Louis University, St Louis, Missouri 63110, USA
    J Infect Dis 190:2096-103. 2004
  7. ncbi request reprint Live attenuated versus inactivated influenza vaccine in infants and young children
    Robert B Belshe
    Saint Louis University Health Sciences Center, St Louis, USA
    N Engl J Med 356:685-96. 2007
  8. ncbi request reprint Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine
    Robert Belshe
    Division of Infectious Diseases and Immunology, Saint Louis University, 3635 Vista Avenue FDT 8N, St Louis, MO 63110, USA
    Expert Rev Vaccines 3:643-54. 2004
  9. pmc Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults
    Robert B Belshe
    Saint Louis University Medical Center, St Louis, MO 63110, United States
    Vaccine 25:6755-63. 2007
  10. ncbi request reprint Translational research on vaccines: influenza as an example
    R B Belshe
    Division of Infectious Diseases and Immunology, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA
    Clin Pharmacol Ther 82:745-9. 2007

Detail Information

Publications49

  1. ncbi request reprint A century of influenza prevention in St. Louis
    Robert B Belshe
    Division of Infectious Diseases, Allergy and Immunology Department of Internal Medicine at Saint Louis University School of Medicine, USA
    Mo Med 109:119-23. 2012
    ..Closing schools, churches, theaters, and other public meeting places reduced the severity of the pandemic in St. Louis. The benefits of contemporary influenza vaccines to prevent influenza and economic disruption are summarized...
  2. pmc Efficacy results of a trial of a herpes simplex vaccine
    Robert B Belshe
    Division of Infectious Diseases, Allergy, and Immunology, Saint Louis University, St Louis, MO 63104, USA
    N Engl J Med 366:34-43. 2012
    ..Efficacy was not observed in men or HSV-1 seropositive women...
  3. ncbi request reprint Current status of live attenuated influenza virus vaccine in the US
    Robert B Belshe
    Health Science Center, Division of Infectious Diseases, Saint Louis University, 3035 Vista at Grand Blvd, St Louis, MO 63110, USA
    Virus Res 103:177-85. 2004
    ..Effectiveness measures, including protection against febrile otitis media and visits to the doctor were demonstrated. Live attenuated vaccine provides a significant new tool to help prevent influenza...
  4. ncbi request reprint Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years
    Robert B Belshe
    Center for Vaccine Development, Saint Louis University School of Medicine, St Louis, MO 63110, USA
    Clin Infect Dis 39:920-7. 2004
    ....
  5. ncbi request reprint Serum antibody responses after intradermal vaccination against influenza
    Robert B Belshe
    Department of Internal Medicine, Division of Infectious Diseases and Immunology, Saint Louis University, St Louis, MO 63110, USA
    N Engl J Med 351:2286-94. 2004
    ..If found to be safe and immunogenic, reduced doses of influenza vaccine given by the intradermal route could increase the number of available doses of vaccine...
  6. ncbi request reprint Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children
    Robert B Belshe
    Saint Louis University, St Louis, Missouri 63110, USA
    J Infect Dis 190:2096-103. 2004
    ..Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted...
  7. ncbi request reprint Live attenuated versus inactivated influenza vaccine in infants and young children
    Robert B Belshe
    Saint Louis University Health Sciences Center, St Louis, USA
    N Engl J Med 356:685-96. 2007
    ..S. advisory bodies. To evaluate alternative vaccine approaches, we compared the safety and efficacy of intranasally administered live attenuated influenza vaccine with those of inactivated vaccine in infants and young children...
  8. ncbi request reprint Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine
    Robert Belshe
    Division of Infectious Diseases and Immunology, Saint Louis University, 3635 Vista Avenue FDT 8N, St Louis, MO 63110, USA
    Expert Rev Vaccines 3:643-54. 2004
    ..In the future it is expected that additional studies will support a broadening of the age range for use with the LAIV to prevent influenza in children and adults...
  9. pmc Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults
    Robert B Belshe
    Saint Louis University Medical Center, St Louis, MO 63110, United States
    Vaccine 25:6755-63. 2007
    ..ID route was not superior to IM vaccine at inducing antibodies. ID vaccine induced significantly more local inflammatory response than IM vaccine...
  10. ncbi request reprint Translational research on vaccines: influenza as an example
    R B Belshe
    Division of Infectious Diseases and Immunology, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA
    Clin Pharmacol Ther 82:745-9. 2007
    ..The pipeline for new influenza vaccines is robust, and recent investment by government and industry in newer vaccines will bring several new products to clinical use...
  11. doi request reprint Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age
    Robert B Belshe
    Saint Louis University Medical Center, St Louis, MO, USA
    Vaccine 26:D10-6. 2008
    ..Hospitalizations and medically significant wheezing were increased in children 6-11 and 6-23 months of age who received LAIV, respectively, but were not increased in children 2-5 years of age...
  12. doi request reprint Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity
    Robert B Belshe
    Saint Louis University Health Science Center, St Louis, MO 63104, USA
    Vaccine 28:2149-56. 2010
    ....
  13. doi request reprint The need for quadrivalent vaccine against seasonal influenza
    Robert B Belshe
    Saint Louis University School of Medicine, USA
    Vaccine 28:D45-53. 2010
    ....
  14. pmc Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant
    Robert B Belshe
    Division of Infectious Diseases and Immunology, Saint Louis University School of Medicine, St Louis, Missouri 63104, USA
    J Infect Dis 203:666-73. 2011
    ..Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus)...
  15. ncbi request reprint Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent
    Robert B Belshe
    Division of Infectious Diseases and Immunology, Saint Louis University, 3635 Vista Avenue FDT 8N, St Louis, MO 63110, USA
    Immunol Allergy Clin North Am 23:745-67. 2003
    ..For children aged 5 to 8 years, two doses are recommended the first year they are immunized with CAIV-T to ensure protection against all strains contained in the vaccine. Thereafter, a single annual revaccination is sufficient...
  16. ncbi request reprint Dose-dependent neutralizing-antibody responses to vaccinia
    Robert B Belshe
    Center for Vaccine Development, Saint Louis University School of Medicine, St Louis, Missouri 63110, USA
    J Infect Dis 189:493-7. 2004
    ..Larger lesion size and fever after vaccination were associated with significantly higher neutralizing-antibody titers after vaccination...
  17. ncbi request reprint Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old
    Robert B Belshe
    Division of Infectious Diseases and Immunology, Saint Louis University, St Louis, Missouri, USA
    J Infect Dis 189:462-70. 2004
    ..PIV3-cp45 vaccine was safe and immunogenic in seronegative children and should be evaluated for efficacy in a phase 3 field trial...
  18. ncbi request reprint Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine
    R B Belshe
    Department of Medicine, Saint Louis University, St Louis, MO 63110, USA
    J Infect Dis 181:1133-7. 2000
    ..Any serum HAI antibody or any nasal wash IgA antibody was correlated with significant protection from H1N1 infection as indicated by vaccine-virus shedding, and high efficacy against H1N1 challenge was demonstrated...
  19. ncbi request reprint Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers
    R B Belshe
    Department of Internal Medicine, Saint Louis University School of Medicine and St Louis Veterans Affairs Medical Center, 3635 Vista Ave FDT 8N St Louis, MO 63110, USA
    J Infect Dis 183:1343-52. 2001
    ....
  20. pmc Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children
    R B Belshe
    Department of Medicine, Saint Louis University, St Louis, Mo 63110 0250, USA
    Philos Trans R Soc Lond B Biol Sci 356:1947-51. 2001
    ..General use of CAIV-T has the potential to significantly reduce the impact of influenza in children and adults...
  21. doi request reprint Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age
    Robert B Belshe
    Saint Louis University Health Science Center, St Louis, MO, USA
    Influenza Other Respi Viruses 4:141-5. 2010
    ..LAIV is currently approved in the United States, South Korea and Hong Kong for individuals 2-49 years of age...
  22. ncbi request reprint Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children
    David I Bernstein
    Division of Infectious Diseases, Cincinnati Children s Hospital Medical Center, OH, USA
    Pediatr Infect Dis J 22:28-34. 2003
    ..The cold-adapted, trivalent influenza vaccine (CAIV-T) may become an option for annual vaccination. However, there is little information regarding the immune response to repeated immunization with CAIV-T...
  23. ncbi request reprint Response to smallpox vaccine in persons immunized in the distant past
    Sharon E Frey
    Department of Medicine, Saint Louis University School of Medicine and National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, MO, USA
    JAMA 289:3295-9. 2003
    ..There is renewed interest in use of smallpox vaccine due to the potential for a bioterrorist attack. This would involve vaccinating health care workers who were previously vaccinated...
  24. ncbi request reprint Dose-related effects of smallpox vaccine
    Sharon E Frey
    Department of Medicine, National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, Saint Louis University School of Medicine, St Louis, USA
    N Engl J Med 346:1275-80. 2002
    ....
  25. pmc Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge
    Sharon E Frey
    Department of Medicine, Saint Louis University School of Medicine and National Institute of Allergy and Infectious Diseases Vaccine Treatment and Evaluation Unit, 1100 S Grand Blvd DRC 8, St Louis, MO 63104, USA
    Vaccine 25:8562-73. 2007
    ..IMVAMUNE vaccination prior to Dryvax reduced virus replication at the Dryvax site, decreased the size of the primary cutaneous lesion, and decreased the time to healing but did not completely ameliorate the immune response...
  26. ncbi request reprint Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax
    Frances K Newman
    Saint Louis University, St Louis, Missouri, USA
    J Infect Dis 187:1319-22. 2003
    ....
  27. ncbi request reprint Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection
    Geoffrey J Gorse
    St Louis Department of Veterans Affairs Medical Center, St Louis University, St Louis, MO 63110, USA
    Vaccine 22:383-97. 2004
    ..Sera from vaccine recipients bound to HIV-1-infected cells, but at levels lower than did infected patient sera...
  28. pmc Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine
    Frances K Newman
    Saint Louis University Vaccine Treatment and Evaluation Unit, St Louis, Missouri 63110, USA
    J Clin Microbiol 41:3154-7. 2003
    ..Therefore, the more sensitive, specific, and reproducible plaque neutralization assay for the detection of antibody to vaccinia virus is the method using a 15-h-incubation time and freshly sonicated vaccinia virus...
  29. pmc Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
    Sharon E Frey
    Saint Louis University School of Medicine, Division of Infectious Diseases and Immunology, St Louis, MO 63104, USA
    Vaccine 28:6367-73. 2010
    ..We describe the first in humans clinical trial of this prophylactic HCV vaccine...
  30. pmc Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins
    Ranjit Ray
    Department of Internal Medicine and Vaccine and Treatment Evaluation Unit, Saint Louis University, St Louis, Missouri, USA
    J Infect Dis 202:862-6. 2010
    ..Neutralizing serum samples had increased affinity levels and displayed >2-fold higher specific activity levels to well-characterized epitopes on E1/E2, especially to the hypervariable region 1 of E2...
  31. pmc Antibody responses to vaccinia membrane proteins after smallpox vaccination
    Steven J Lawrence
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO 63110, USA
    J Infect Dis 196:220-9. 2007
    ..Vaccinia virus (VV) membrane proteins are candidates for orthopoxvirus subunit vaccines and potential targets for therapeutic antibodies. Human antibody responses to these proteins after VV vaccination have not been well characterized...
  32. ncbi request reprint Clinical responses to undiluted and diluted smallpox vaccine
    Sharon E Frey
    Department of Medicine, National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, Saint Louis University School of Medicine, St Louis, USA
    N Engl J Med 346:1265-74. 2002
    ..To evaluate the potential to increase the supply of smallpox vaccine (vaccinia virus), we compared the response to vaccination with 10(8.1), 10(7.2), and 10(7.0) plaque-forming units (pfu) of vaccinia virus per milliliter...
  33. ncbi request reprint The immunogenetics of smallpox vaccination
    Samuel L Stanley
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Infect Dis 196:212-9. 2007
    ....
  34. ncbi request reprint The genetic archaeology of influenza
    Daniel F Hoft
    Division of Infectious Disease and Immunology, Department of Internal Medicine and Molecular Microbiology, Saint Louis University, St Louis, USA
    N Engl J Med 351:2550-1. 2004
  35. ncbi request reprint Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions
    Getahun Abate
    Department of Internal Medicine, Saint Louis University, St Louis, Missouri 63110, USA
    J Infect Dis 192:1362-71. 2005
    ..CFSE-based flow-cytometric assays will be useful in evaluating cell-mediated immune responses induced by new smallpox vaccines...
  36. ncbi request reprint The origins of pandemic influenza--lessons from the 1918 virus
    Robert B Belshe
    Division of Infectious Diseases and Immunology, Department of Internal Medicine, Saint Louis University, St Louis, USA
    N Engl J Med 353:2209-11. 2005
  37. ncbi request reprint Poxvirus zoonoses--putting pocks into context
    Sharon E Frey
    Division of Infectious Diseases and Immunology, Saint Louis University, St Louis, USA
    N Engl J Med 350:324-7. 2004
  38. ncbi request reprint Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults
    David van Duin
    Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06520, USA
    J Infect Dis 195:1590-7. 2007
    ..We examined whether CD80 and CD86 expression vary with aging and predict response to the trivalent inactivated influenza vaccine...
  39. ncbi request reprint Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination
    Kenneth M Zangwill
    School of Medicine, UCLA Harbor UCLA Medical Center, Torrance, CA, USA
    Pediatr Infect Dis J 23:189-97. 2004
    ....
  40. ncbi request reprint Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
    Deborah Lee
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 190:903-7. 2004
    ..4, P =.1, and P =.7, respectively). Persons who acquire HIV-1 infection while enrolled in HIV-1 vaccine trials can be successfully followed after infection, to determine whether vaccines alter the course of HIV-1 infection...
  41. ncbi request reprint Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination
    Jeffrey S Kennedy
    Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    J Infect Dis 190:1286-94. 2004
    ..Postvaccination cell-mediated immune (CMI) responses have not been compared by use of controlled trials in previously vaccinated (vaccinia-nonnaive) and nonvaccinated (vaccinia-naive) individuals...
  42. ncbi request reprint Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children
    Pedro A Piedra
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatrics 110:662-72. 2002
    ..To provide additional information on the safety of trivalent, cold-adapted influenza vaccine (CAIV-T) in children...
  43. ncbi request reprint A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants
    Ruth A Karron
    Pediatr Infect Dis J 22:394-405. 2003
    ..Parainfluenza type 3 virus (PIV-3) infections cause lower respiratory tract illness in children throughout the world. A licensed PIV-3 vaccine is not yet available...
  44. ncbi request reprint Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants
    Ruth A Karron
    Center for Immunization Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Infect Dis 191:1093-104. 2005
    ..Recombination technology can be used to create live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenuating mutations...
  45. doi request reprint Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States
    Bryan R Luce
    United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    Vaccine 26:2841-8. 2008
    ....
  46. ncbi request reprint Live attenuated intranasal influenza vaccine
    Robert B Belshe
    Vaccine 20:3429-30. 2002
  47. ncbi request reprint Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers
    Shabir A Madhi
    University of the Witwatersrand Medical Research Council Respiratory and Meningeal Pathogens Research Unit, South Africa
    Vaccine 24:2432-9. 2006
    ..This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate...
  48. pmc The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines
    Peter F Wright
    Vanderbilt University, Nashville, TN, USA
    Vaccine 25:7372-8. 2007
    ..The impact of RSV during this surveillance will inform the design of future efficacy studies with RSV vaccines...
  49. ncbi request reprint The burden of influenza and strategies for prevention
    Robert B Belshe
    St Louis University, St Louis, USA
    Manag Care 16:2-6; discussion 17-9. 2007